Axillary Management in the Neoadjuvant Setting
The underarm operation after preoperative treatment is planned from the original nodal findings and the response to treatment.
The key things to know
- Original nodal status remains important after a good response.
- Targeted dissection may be suitable for selected patients.
- Residual disease requires multidisciplinary review.
Establishing the initial nodal status
Before neoadjuvant treatment, the team examines the axilla and may use ultrasound and needle sampling of suspicious nodes. If a node is biopsy-proven to contain cancer, a marker can help identify it later. This record is important even if the node becomes normal on examination or imaging. A response does not erase the starting information used to plan safe care.
When limited surgery may be possible
For patients initially without proven nodal involvement, sentinel-node biopsy may be performed after systemic treatment when indicated. Some patients whose involved nodes respond can undergo a carefully designed limited staging procedure. Targeted axillary dissection combines removal of the previously marked involved node with sentinel nodes. Technique, retrieval of the marked node, and the clinical setting influence reliability.
If disease remains
Residual cancer in nodes after treatment may lead to a recommendation for axillary clearance and/or regional radiotherapy, depending on the situation and current specialist guidance. Management of very small residual deposits and approaches to reducing surgery continue to evolve. A clinical trial may be relevant. Do not assume that the same rules used before systemic treatment apply unchanged afterward.
Discussing accuracy and arm health
The team balances accurate assessment and cancer control against arm swelling, sensory changes, and shoulder problems. Ask what will happen if mapping fails or the marked node cannot be found, and whether this could mean another operation. Ensure you receive a rehabilitation plan and a named contact for postoperative concerns. Final pathology may also influence further drug treatment.
Take these questions to your appointment
- Will my marked node be removed?
- What is the plan if residual cancer or failed mapping is found?
Sources & review
This is original educational content based on the sources below, not reproduced textbook material. Website supervisor: Dr. Nizar Ismail. Individual medical review of this article is pending.
- NCI: Breast Cancer Treatment PDQ ↗
- ASBrS: Axillary Management Resource Guide (2026) ↗
- ASBrS: Technical Considerations for Axillary Surgery (2026) ↗
This information cannot replace diagnosis or a personal treatment plan. Consult your care team about symptoms or decisions about your treatment.
